UNSPSC 51111602: Cytarabine

This classification denotes an antimetabolite, antineoplastic, antiviral agent, and immunosuppressive agent with the molecular formula C9H13N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04079A1RDZ, chemically known as 4-amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine but generally known as cytarabine, which bears US NIH Compound Identifier 596. European Medicines Agency schedules Cytarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06880MIG.

UNSPSC 51111602 Cytarabine is a Commodity code for a specific chemotherapy pharmaceutical agent. State and local governments procure cytarabine primarily through state health and human services agencies and Medicaid programs that manage pharmacy benefits and drug procurement for eligible populations. The work involves sourcing, contracting, and supply chain management for this oncology medication, which may be procured directly from manufacturers, through group purchasing organizations, pharmacy benefit managers, or wholesale distributors depending on the state's pharmacy benefit strategy and cost-containment objectives.

The issuing-body mix for this code centers on state health departments and Medicaid agencies. The Texas Health and Human Services Commission recently posted Request for Information HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory market-research phase examining whether the state can establish direct relationships between its pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and reduce costs. The RFI solicited detailed vendor responses regarding direct-contracting capacity with self-insured employee group health plans and state agencies, experience with negotiated net pricing models without rebates, and capability for value-based or outcomes-based agreements. This preliminary information-gathering effort signals that Texas intends to develop a formal procurement strategy for pharmacy benefit management that may reshape how the state sources individual medications such as cytarabine. The RFI documentation contained no award value, budget range, set-aside designations, or formal evaluation criteria at the information-gathering stage, with the state planning to issue a formal RFP only after analyzing vendor responses. No other recent state or local solicitations for cytarabine appear in the current activity record, limiting visibility into broader geographic procurement patterns or the activity level across other jurisdictions.